BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31161871)

  • 1. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
    Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
    MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
    Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
    Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
    Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
    Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin.
    Ansell SM
    Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
    Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
    Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
    Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
    Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
    Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.